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Abstract: In this systematic review, we will consider and debate studies that have explored
the effects of ω-3 polyunsaturated fatty acids (PUFAs) in three major, and somehow related,
developmental psychiatric disorders: Autism, Attention Deficit and Hyperactivity disorder and
Psychosis. The impact ofω-3 PUFAs on clinical symptoms and, if possible, brain trajectory in children
and adolescents suffering from these illnesses will be reviewed and discussed, considering the
biological plausibility of the effects of omega-3 fatty acids, together with their potential perspectives
in the field. Heterogeneity in study designs will be discussed in the light of differences in results and
interpretation of studies carried out so far.
Keywords: neurodevelopment; omega-3; PUFAs; eicosapentaenoic acid (EPA); docosahexaenoic
acid (DHA); autism; attention deficit hyperactivity disorder (ADHD); ultra-high risk for psychosis;
first psychotic episode
1. Introduction
Mental disorders, despite the growing pharmacological discoveries, will gradually increase in
the next decades [1]. Interestingly, among the hypothetical factors that have been reported to increase
the incidence of psychopathologies in individuals in developed countries there was the modification
of diet habits, mainly due to the transition to more calorically dense ones and to lower level of
physical activity [2]. In particular, in recent years, an increased interest has been directed towards the
investigation ofω-3 PUFAs in the treatment of different mental disorders [3].
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Essential Fatty Acids (EFAs) are obtained from plants or other organisms that possess enzymatic
pathways for their synthesis. EFAs are therefore essential dietary nutrients for survival of humans
and other mammals because of the absence of the desaturase (∆)12 and ∆ 15 enzymes necessary
to insert a double bond at the n ω-6 or -3 position of a fatty acid carbon chain [4]. There are
two types of naturally occurring EFAs in the body, the ω-6 series derived from cis-linoleic acid
(LA, 18:2) and theω-3 series derived from α-linolenic acid (ALA, 18:3). Once obtained from the diet,
LA and ALA are further metabolized in the liver by the enzymes ∆6 and ∆5 desaturases to generate
long-chain PUFAs (LCPUFAs) as arachidonic acid (AA, 20:4,ω-6), eicosapentaenoic acid (EPA, 20:5,
ω-3) and docosahexaenoic acid (DHA, 22:6, ω-3). The enzymatic metabolic products of 20 carbon
LCPUFAs are called eicosanoids and they include prostaglandins, thromboxanes, and leukotrienes:
in general, AA-derived eicosanoids have mainly pro-inflammatory properties, whereas EPA derived
eicosanoids are rather less inflammatory. Furthermore, recent studies have identified a novel group of
mediators termed E- and D-series resolvins formed from EPA and DHA, respectively. Together with
neuroprotectin D1 formed from DHA via several reactions, these mediators appear to exert strong
inflammation resolving effects [5]. This suggests that LCPUFAs form precursors to both pro- and
anti-inflammatory molecules, and the balance between these mutually antagonistic compounds could
determine the final outcome of the disease process [6].
Moreover, LCPUFAs are incorporated into membrane phospholipids and the incorporation of
DHA takes place in uniquely high levels in the central nervous system [7]. This accumulation in the
brain starts during the brain growth spurt in the intrauterine stage and continues up to two years
of age, then maintaining high levels throughout the life span [8]. The intrauterine LCPUFAs supply
occurs via transfer of non-esterified PUFA mainly derived from the maternal circulation across the
placenta [9]. Post-natal accumulation of LCPUFAs in infant tissues is supported by maternal transfer
of LCPUFAs through breastmilk, and blood levels of LCPUFAs in breast-fed infants remain higher
than maternal levels for some time postnatally [10]. With respect to the functional effects of LCPUFAs
supplementation in infancy, the most accepted developmental effect is an increased rate of visual
acuity development, which seems to be explained solely by DHA [11]. Once high levels of DHA
are achieved in the brain, these are maintained during later life, nevertheless this presumably still
depends on an optimal dietary supply, as dietary intake of DHA from fish in adults has been shown
to be the dominant determinant of DHA levels in various lipid pools [12]. In agreement with these
observations, the implementation of LCPUFAs in psychiatric disorders stemmed from the fact that the
brain is composed, in large part, of theω-3 PUFAs, which have been shown to have neuroprotective
properties, especially in producing modification of the synaptic membrane [13]. Indeed, they modulate
brain cell signaling, including monoamine regulation, and are involved in the modification of receptor
properties or the activation of signal transduction by receptors [14–17], which may explain their role in
the onset of certain psychiatric diseases [18,19].
Omega-3 PUFAs deficiencies have been reported in people with a wide range of mental
disorders, including attention deficit hyperactivity disorder (ADHD), depression, schizophrenia (SCZ),
and Autism Spectrum Disorder (ASD) [13,16,20–24]. In particular, previous studies observed significant
abnormalities in the fatty acid composition of peripheral tissues from drug-naïve first-episode patients
with schizophrenia (SCZ) relative to normal controls, including deficits in ω-3 and ω-6 PUFAs,
which are partially normalized by chronic antipsychotic treatment [24]. Similarly, medication-naïve
first-episode psychotic patients also showed erythrocyte DHA deficits compared with healthy
controls [25,26], and a recent meta-analysis of 18 case-control studies reported significant DHA deficits
in patients with SCZ [27], the presence of reduced concentrations of ω-3 PUFAs has been reported in
children with ASD [28]. Further confirming the key role played byω-3 PUFAs in neurodevelopment,
data from observational studies consistently indicated lowerω-3 PUFAs blood levels (especially DHA)
in children with ADHD compared with their typically developing peers [29,30]. Several studies
accordingly reported a significant negative relationship between blood ω-3 PUFAs status and ADHD
symptoms: low blood levels of DHA and EPA have been shown to be associated with ADHD symptoms
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such as inattention and hyperactivity [31–33]. Based on this evidence, an increasing number of
intervention studies have been conducted to evaluate the efficacy of ω-3 PUFAs supplementation for
the treatment of children with ADHD.
In this context, the aim of this systematic review is to provide an updated account of the evidence
of the efficacy and safety exerted by ω-3 PUFAs supplementation in ASD, ADHD and early psychotic
symptoms (ultra-high risk of psychosis and first psychotic episode) to check the hypothesis that
ω-3 PUFAs might be useful either sole or in augmentation as a potential therapy for these disabling
psychiatric disorders.
2. Results
2.1. Omega-3 in Psychosis
The worldwide prevalence of psychosis has been estimated to be approximately 1% [12]. Notably,
it has been reported that this mental disorder leads to long term disability [34] by disrupting
social and family relationships, which in turn determines severe educational and occupational
impairment, lost productivity, unemployment, physical illness, and premature mortality [35]. The main
symptoms experienced by psychotic patients are auditory hallucinations and delusional ideation [36].
Psychotic illnesses are usually preceded by a prodromal period, lasting one to three years [37],
which is characterized by a range of non-specific behavioral and psychological symptoms, functional
deterioration, and by both attenuated positive symptoms and brief limited intermittent psychotic
symptoms [38]. Prospective studies of individuals who later develop psychosis have given the
opportunity to analyze the potential risk factors, such as heritability, linked to this mental disorder.
Over the past decade, the term “ultra-high-risk” (UHR) identifies adolescents and young adults who
are at increased risk of developing full blown psychotic symptoms; among these subjects about 22%
to 40% shows transition to overt disease within 12 months [39–41]. Therefore, interventions that
prevent or delay transition to psychosis from the prodromal phase may be clinically and economically
important [42]. It has been suggested that the treatment withω-3 PUFAs have some potential beneficial
effects on psychotic symptoms. This evidence, along with the findings showing lower levels ofω-3
and ω-6 PUFAs in patients with SCZ compared to healthy controls [24–27,43], has allowed to put
forward the “membrane phospholipid hypothesis” of SCZ [44,45]. Similarly, many epidemiological
or observational studies also suggested that greater dietary intake of fish orω-3 PUFAs is linked to a
general reduced risk of psychosis [46–49]. In this paragraph, we summarized all randomized clinical
trial studies (RCTs) with the final aim of providing a clearer picture of the impact of EPA and DHA in
UHR subjects and in first episode psychosis patients.
To date, only five RCTs explored the role ofω-3 PUFAs supplementation in UHR patients or in
first episode of psychosis (Table 1).
2.1.1. Ultra-high-risk Patients
The study with the larger sample is a multicenter RCT study carried out by McGorry et al. [50]
on 304 subjects meeting the criteria for being “at risk” to develop psychosis. They were randomized
to daily dose of 1.4 g of ω-3 PUFAs (EPA 840 mg + DHA 560 mg) or placebo (paraffin oil), without
the add-on therapy with neuroleptics or mood stabilizers but with the use of antidepressants and
benzodiazepines. In addition, 20 or fewer sessions of cognitive behavioral case management (CBCM)
were administered over the 6-months study period with an additional follow up of six months.
The primary outcome was transition to psychosis status at 6 months. The authors showed no significant
differences between the transition rates to psychosis and outcomes between the groups, with low
transition rates and overall symptomatic functional improvement in both arms. These results could
be probably due to the efficacy of CBCM and antidepressants that both groups have received, which
may have hidden the effectiveness of ω-3 PUFAs. In contrast, Amminger et al. (2010) [46] in a
12-week RCT reported the efficacy of ω-3 PUFAs pills (containing 700 mg of eicosapentaenoic acid
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and 480 mg of docosahexaenoic acid) versus placebo (coconut oil + Vit E 7.6 mg) in 81 individuals
at UHR for psychosis in addition to antidepressants and psychological treatments. Interestingly,
no difference for side effects were observed between theω-3 PUFAs and placebo groups. The positive
effect ofω-3 PUFAs treatment was further confirmed by the same research group in three other studies
employing the same or part of the sample [51–53], showing reduced risk of progression to psychosis
over a long follow-up period (median 6.7 years). Amminger et al. [52] also reported that the UHR
subjects with higher levels of erythrocyte membrane ALA may specifically benefit fromω-3 PUFAs
treatment. Interestingly, Smesny et al. [53] demonstrated that ω-3 PUFAs supplementation may act by
normalizing intracellular phospholipase A2 activity and ∆-6-desaturase-mediated metabolism of ω-3
andω-6 PUFAs.
2.1.2. First Episode Psychosis
We identified two RCT studies reporting contrasting results. Pawelczy [54] demonstrated a
significant difference betweenω-3 PUFAs and placebo in first episode of psychosis patients, whereas
Berger [55] found no significant difference between the same groups. These discordant results may
be due to different doses ofω-3 PUFAs, administration periods (6 vs. 3 months), type ofω-3 PUFAs
(EPA + DHA vs. EPA) or patients’ clinical characteristics. Specifically, Pawelczyk found after
a period of six months a significant symptoms improvement in ω-3 PUFAs group (2.2 g/day:
EPA 1320 mg + DHA 880 mg) vs. placebo in a sample of 71 patients suffering from first-episode
psychosis, as add-on treatment to antipsychotics. In contrast, Berger [55] observed a higher response
rate to antipsychotic drugs (risperidone, olanzapine or quetiapine) at Week 6 for first-episode
psychosis patients supplemented with ethyl-EPA (E-EPA at 2 g/day) in comparison to placebo,
which disappeared at Week 12. Additionally, they found that patients on E-EPA compared to those on
placebo: (a) needed 20% less antipsychotic medication; and (b) had less extrapyramidal, gastrointestinal
and sexual side effects. Therefore, these results suggest that E-EPA accelerate treatment response
and ameliorate the tolerability of antipsychotics, particularly during the first 4–6 weeks of treatment.
Interestingly, the same research group in 2008 [56] by means of proton magnetic resonance spectroscopy
showed that 12-weeks of E-EPA augmentation in first-episode psychosis patients increased the
levels of glutathione in temporal lobes, which is involved in oxidative stress [57] and/or apoptotic
activity [58], and the ratio of glutamate/glutamine in the left hippocampus. These changes could
partially explain the neuroprotective effects of E-EPA and may potentially ultimately help in preventing
neurodegenerative processes taking places in psychotic disorders.
Interestingly, although the evidence reporting the effectiveness of ω-3 PUFAs in psychosis is still
on its infancy, several meta-analyses conducted in patients affected by SCZ [59–63], at risk to develop
psychosis [42,64–66], or at first episode of psychosis [67–69] further support the abovementioned
results. Future studies with larger and more homogeneous sample are needed to elucidate the efficacy
ofω-3 PUFAs in UHR subjects or in first episode of psychosis.
2.2. Omega-3 and Autism
Autism spectrum disorders (ASD) refers to a group of conditions related to neurodevelopment
including impaired social behavior, restricted communication, repetitive activities and limited interests.
The etiology is primarily linked to genetics but also environmental factors may play a relevant role.
The World Health Organization (WHO) updated the prevalence estimating that worldwide
1 in 160 children has an ASD. The disorder is evident in early childhood and tends to persist into
adolescence and adulthood.
Despite progress in medically treating ASD, there is an increasing interest in alternative treatments
including melatonin, vitamins, a gluten- and casein-free diet, and the use of ω-3 PUFAs, although
the biological plausibility is quite different among these alternatives. Indeed, ω-3 PUFAs and their
metabolic products offer a solid basis, since they have been implicated in ASD via their roles in brain
structure and function, neurotransmission, cell membrane structure and microdomain organization,
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inflammation, immunity and oxidative stress. There is accumulating data to support that EPA and
DHA are important for brain structure and function and have been advocated for the treatment of
multiple neurodevelopmental disorders including mood disorders, schizophrenia, ADHD, and ASD.
Abnormality in blood levels of ω-3 PUFAs has been reported in psychiatric disorders including,
but not limited to, ADHD and ASD [23–25]. In particular, compared with typically developed, ASD
populations had a lower DHA, EPA and ARA and higher total ω-6 PUFA to ω-3 PUFAs ratio [70].
Elevated levels of several peripheral pro-inflammatory cytokines and nuclear factor Kappa B (NF-κB,
a transcription factor involved in inflammatory signaling pathways) has been reported in children
with ASD [70].
In this paragraph, we provide an update regarding the effects of ω-3 PUFAs supplementation
on symptoms of ASD in children. We included RCTs reporting outcome measures as core symptoms
of ASD (including social interaction, communication and repetitive restrictive behaviors or interests)
and symptoms or behaviors associated with ASD (e.g., hyperactivity).
We identified three RCT studies (Table 1). The first RCT analyzed [71] is an internet-based RCT
(IB-RCT) conducted to examine the feasibility of a novel internet-based design in order to evaluate
the safety and efficacy ofω-3 PUFAs in ASD. Children (n = 57) affected by ASD between the age of
five and eight were randomly assigned to six weeks of treatment (n = 29) with 1.3 g of ω-3 PUFAs
(and 1.1 g of DHA + EPA) or an identical placebo (n = 28).
The primary outcome measure was defined a priori as the change in hyperactivity on the Aberrant
Behavior Checklist (ABC-H, parent and teacher) over the six-week treatment period: children in the
treatment group did have greater mean improvements in hyperactivity compared to the placebo
group (a 5.3 point reduction in the ABC-H in the ω-3 PUFAs group vs. 3.4 in the placebo group),
but this difference was not significant. Concerning the secondary outcome measures, this study found
statistically significant improvements in theω-3 PUFAs group in two secondary outcome measures,
the stereotypy and lethargy subscales of the ABC.
The second RCT [72] as conducted by Voigt and presented different conclusions. In particular,
48 children 3–10 years of age with ASD were randomized to receive a dietary DHA supplementation
of 200 mg/day for six months (n = 24) or placebo (n = 24).
The authors did not show any improvement in core symptoms of autism or a broad range of
associated developmental and behavioral difficulties. They only found a favorable change in functional
communication reported by teachers in children with autism who received DHA supplementation but
further investigations are required.
The third study [73] is a 16-week RCT that evaluated the efficacy of supplementation with large
doses of ARA added to DHA (n = 7) (240 mg of ARA-enriched triglyceride containing 40 mg/capsule
each of ARA and DHA, and 0.16 mg/capsule of astaxanthin) or placebo (n = 6) in 13 participants in
the age range 6–28 years who had autistic disorder. The results suggest that supplementation with
larger ARA doses added to DHA improves impaired social interaction in individuals with ASD.
The treatment effect sizes for ABC social withdrawal (treatment group: 0.88 vs. placebo: 0.54) and
Social Responsiveness Scale (SRS) communication (treatment group: 0.87 vs. placebo: 0.44) subscales
were more favorable for the treatment group than for the placebo group.
In conclusion, these findings reported a small but not significant benefit of ω-3 PUFAs
supplementation in children with ASD. Data in this field are few and the sample size is often too
limited. This is in agreement with recent systematic reviews and meta-analysis [70,74] concluding that,
based on the current evidence, ω-3 PUFAs supplementation cannot be recommended as an alternative
to support behavioral therapies for ASD children, but could be used to complement other therapies.
Large high-quality RCTs are still required to further clarify the role of ω-3 PUFAs on functional
outcomes in this population and to draw conclusions.
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Table 1. RCTs ofω-3 PUFAs supplementation in early psychotic symptoms (ultra-high risk of psychosis and first psychotic episode), ADHD and ASD.
Ultra Hight Risk Psychosis
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[46]
76 of 81
participants
(93.8%)
completed the
intervention
(aged 13–25)
MONO 1.2 g/day (EPA 700 mg + DHA
480 mg) or PLACEBO + 7.6 mg Vit E 12 + 40 of follow up
Primary outcome
transition to psychosis
Secondary outcomes
included symptomatic
and functional changes
A significant reduction inω-3 PUFAs group of
positive symptoms, negative symptoms,
and general symptoms and improved
functioning compared with placebo.
[51] 15 MONO 1.2 g (EPA + DHA) day ORPLACEBO 12
PANSS, MADRS
GAF
Udvalg for Kliniske
Undersøgelser
(SCALE for SIDE
EFFECTS)
ω-3 PUFA significantly improved functioning
and reduced psychiatric symptoms, compared
with placebo. Side effects did not differ between
the treatment groups
[50]
304 (aged
between 13
and 40 years)
MONO 1.4 g (EPA + DHA) or PLACEBO
+ CBCM 24
Transition to psychosis
status at 6 months
BPRS
SANS
MADRS
YMRS
SOFAS
GF: S
GF: R
ω-3 PUFAs are not effective under conditions
where good quality, evidence-based
psychosocial treatment is available
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Table 1. Cont.
First episode Psychosis
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[55]
ADD ON 2 g
EPA OR
PLACEBO
80 FEP but only 69 were eligible
for analysis 12
Primary outcome
PANSS
GAF
CGI
Secondary
outcome measures:
tolerability measures and
cumulative anti psychotic
dose
EPA no efficacy on specific psychotic symptoms
[54] 71 (aged 16–35) ADD ON 2.2 g/day (EPA + DHA) orPLACEBO 26 PANSS
Significant differences between the study arms
regarding total PANSS score change favoring
ω-3 PUFA.
ADHD
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[75] 50
ADD ON
ATX + 180 mg EPA + 120 mg DHA
OR ATX
16 KSADS-PLCPRS
Study group had greater but not statistically
significant (p = 0.08) reduction in
CPRS ADHD scores.
[88] 40
ADD ON
MPH + 241 mg DHA + 33 mg
EPA + 180 mg omega 6 per day OR
MPH + placebo
10 ADHD-RSSide-Effect questionnaire
ADHD-RS scores decreased significantly within
both groups but total score and scores of
inattention, hyperactivity, and impulsivity were
not significantly different between the groups.
[89] 90
ADD ON
558 mg EPA + 174 mg DHA + 60 mg
GLA per day OR MPH + 558 mg
EPA + 174 mg DHA + 60 mg
GLA per day OR MPH
48 ADHD-RSCGI-S
No significant differences between
MPH + Omega-3/6 and MPH alone.
Significant differences between Omega-3/6 and
MPH + Omega-3/6 in ADHD Total score and
Hyperactivity-Impulsivity indicating a stronger
effect for combined treatment compared with
Omega-3/6.
[78] 69
ADD ON
MPH + 240 mg DHA + 360 mg EPA
per day OR MPH + placebo
8 ADHD-RS
Both groups had a significant improvement of
ADHD symptoms but there was no significant
difference between them.
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Table 1. Cont.
ADHD
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[79] 40
MONO
650 mg DHA + 650 mg EPA per day OR
placebo (margarine)
16
fMRI scan with a
Go-No-Go task;
CBCL;
SWAN
Scores on CBCL attention problems were
reduced in comparison with placebo (p < 0.001).
No effect of EPA/DHA on Go-No-Go task or on
fMRI measures.
[80] 26
MONO
20–25 mg/kg EPA + 8.5 − 10.5 mg/kg
DHA per day OR placebo (sunflower oil)
8
SWAN
CPRS-L
CPT
Go-No-Go test
CPRS subscales measuring symptoms of
inattention and impulsivity showed a significant
improvement in both groups; study group
showed a greater but not statistically significant
improvement.
[97] 85
MONO
1 g omega 3 per day OR MPH OR
placebo
4
CPRS
CTRS
KBIT (for IQ)
Significant association between treatment with
MPH or omega 3 and improvement in
hyperactivity-impulsivity and combined
subtypes. No significant association between
treatment with placebo and improvement.
[95] 17 MONO1 g ALA per day OR placebo (lactose) 8
MOXO-CPT
CPRS
CTRS
No significant differences between groups in the
changes from pre- to post-supplementation
values on CPRS, CTRS and MOXO-CPT
[81] 92
MONO
500 mg EPA + 2.7 mg DHA and 10 mg
Vitamin E per day OR placebo (rape seed
oil and medium-chain triglycerides)
15 CPRSCTRS
Supplementation improved CTRS
inattention/cognitive subscale (p = 0.04) but not
Conners’ total score. In oppositional
childrenplacebo (margarine) (n = 48) CTRS total
score improved ≥25% in 48% of the children in
study group vs. 9% for placebo (p = 0.001).
[90] 103
ADD ON
Ritalin + 635 mg EPA + 195 mg DHA +
100 mg other omega 3 fatty acids per day
OR Ritalin + placebo (olive oil)
8 ASQ-P Significant improvement from week in ASQ-Pscores of the omega-3 group.
[76] 64
MONO
558 mg EPA + 174 mg DHA + 60 mg
GLA per day OR placebo (olive oil)
12 ADHD-RSCGI-S
Improvement on CGI-S in the study group
significantly greater than in the placebo group.
More than half of all children did not respond to
treatment. However, 26% in the study group
responded versus 7% in the placebo group.
Int. J. Mol. Sci. 2017, 18, 2608 9 of 25
Table 1. Cont.
ADHD
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[83] 147
MONO
300 mg PS and 120 mg EPA + DHA
(EPA/DHA ratio of 2:1) per day
OR placebo (cellulose)
15
CPRS
CTRS
SDQ
CHQ-PF50
Significant reduction in the Restless/Impulsive
subscale of CPRS and in Parental Emotional
Impact subscale of the CHQ in the study group
compared to placebo group.
[91] 76
MONO
558 mg EPA + 174 mg DHA + 60 mg
GLA + 9.6 mg vitamin E per day OR
placebo (medium chain triglycerides)
12
CTRS
CPRS
BIS
LC-PUFA supplementation did not improve
ADHD symptoms at 12 weeks follow-up.
[84] 87
MONO
1109 mg EPA + 108 mg DHA + Vitamine
E per day or 264 mg EPA, 1032 mg DHA
+ Vitamine E per day OR placebo
(safflower oil)
48
word reading and spelling
subtests from WIAT-III
Vocabulary subtest from
WISC-III
CPRS
TEA-ch
Go/No-go
No significant treatment effects for literacy,
cognition or parent-reported behavior.
[85] 87 ADHD
MONO
1109 mg EPA + 108 mg DHA + Vitamine
E per day OR 264 mg EPA + 1032 mg
DHA + Vitamine E per day OR placebo
(safflower oil)
16
word reading and spelling
subtests from WIAT-III
Vocabulary subtest from
WISC-III
CPRS
TEA-ch
Go/No-go
No significant treatment effects for literacy,
cognition or parent-reported behavior.
[98] 94
ADD ON
592.74 mg omega 3 + 361.5 mg omega 6
per day + MPH OR placebo
(sunflower oil) + MPH
24 11-item checklistcompleted by the parents.
Significant improvement in the study group
compared with the placebo group (p < 0.01) at
12 weeks in restlessness, aggressiveness,
completing work and academic performance.
Significant improvement became evident at
24 weeks (p < 0.05) also for inattention,
impulsiveness, and cooperation with parents
and teachers.
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Table 1. Cont.
ADHD
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[96] 63
MONO
480 mg LA + 120 mg ALA + 190 mg
mineral oil + 10 mg a-tocopherol per day
OR placebo (vitamin c)
7
DSM-IV questionnaire for
ADHD
Abbreviated CPRS/CTRS
TOVA
Both groups ameliorated some of the symptoms,
but no significant differences were found
between the groups in any of variables explored
[77] 150
ADD ON
Ritalin + 100–400 mg EPA per day
depending on weight OR Ritalin + 22 mg
zinc sulfate OR Ritalin + placebo (sugar)
8 CPRSCTRS
A significant decreasing trend in all three groups
was observed. No significant differences
between groups on average Conners’ scores
at Week 8.
[92] 50
MONO
480 mg DHA + 80 mg EPA + 40 mg AA +
96 mg GLA per day OR placebo
(olive oil)
16
ASQ-Parents/Teachers
DBD-Parents/Teachers
CPT
WJ-R
ASQ: Significant decrease from baseline within
both placebo and PUFA group but no treatment
effect.
DBD: For conduct problems rated by parents
and for attention symptoms rated by teachers,
study group showed significant improvement
over the placebo group.
[86] 60
MONO
156 mg EPA + 95 mg DHA containing
300 mg PL-omega 3 per day OR 153 mg
EPA + 96 mg DHA containing FO OR
placebo (rapeseed oil)
12
TOVA
ASQ
CBCL 4–18
Total TOVA score was significantly affected by
the treatments: PL-omega 3 > FO > placebo.
The proportion of subjects with normative
scores in the PL-omega-3 group (11/18) was
statistically different from that of the placebo
group (3/21), but not from the FO group (7/21).
The PL-omega-3 and, to a limited extent, the FO
group significantly improved the executive
functioning in almost all TOVA-adjusted
variables compared with placebo
[99] 54
ADD ON
MPH + 345 mg DHA per day OR MPH +
not specified placebo
16
TOVA
Children’s Color Trails
Test
CBCL
CPRS
No statistically significant improvement in any
measure of ADHD symptoms.
[87] 95
MONO
600 mg EPA + 120 mg DHA + 15 mg of
vitamin E per day OR Placebo (olive oil)
16
DISYPS-II
CBCL
TRF
HAWIK IV
KITAP 6–10 years
TAP 10–18 years
Omega-3 improved working memory function,
but had no effect on other cognitive measures
and on DISYPS-II, CBCL or TRF.
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Table 1. Cont.
Elevated ADHD Symptoms
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[82] 112
MONO
21.9/29.2 mg EPA + 16.5/22 mg DHA +
300/400 mg natural mono-unsaturated
olive oil + 0.675/0.9 mg vitamin E per
day depending on age OR placebo (olive
oil, lecithin, coconut oil and β-carotene)
14
CPRS
COMPASS cognitive
battery
TOVA
BRUMS
EEG
CGI
No significant difference between treatment
groups on CPRS. Significant treatment effects on
CPRS scores of hyperactivity, attention, learning
and probability of ADHD for children who did
not meet criteria for combined hyperactivity and
inattention. Significant improvements in the
study group on delayed working memory
between baseline and Week 8.
[93] 104
MONO
558 mg EPA + 174 mg DHA+ 60 mg GLA
+ 10.8 mg vitamin E per day, alone or
associated with a multivitamin/mineral
supplement OR placebo (palm oil)
15 CPRSCTRS
CPRS: Significant improvements in the PUFA
groups (combined) compared with placebo on
core ADHD symptoms (inattention,
hyperactivity, and impulsivity) and on ratings of
oppositional behavior
CTRS: No significant results.
[94] 109
MONO
558 mg EPA + 174 mg DHA+ 60 mg GLA
+ 10.8 mg vitamin E per day, alone or
associated with a multivitamin/mineral
supplement OR placebo (palm oil)
15
CPRS
CTRS
Creature-Counting test
Short form of WISC-III
Inspection time
Rey Auditory-Verbal
Learning Test
Knock and Tap NEPSY
subtest
Stroop color–word test
Creature Counting: Over 15 weeks, there was a
significant improvement in the PUFA groups
compared to placebo.
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Table 1. Cont.
Autism
Study N. Sample N-PUFA Assessed Daily Amounts Duration (Weeks) Outcome Measures Major Finding
[71] 57 1.3 g ofω-3 PUFA per day OR placebo 6
the change in
hyperactivity on the
Aberrant Behavior
Checklist (ABC-H,
parent and teacher)
Secondary outcomes
included changes in the
other subscales of the
ABC and the Social
Responsiveness Scale
(SRS).
Children in the omega-3 fatty acid group had a
greater reduction in hyperactivity, but the
difference was not statistically significant.
This study found statistically significant
improvements in theω-3 PUFA group in the
stereotypy and lethargy subscales of the ABC.
[72] 48 DHA supplementation of 200 mg/dayOR placebo. 26
The primary outcome
measure was a significant
positive response on the
Clinical Global
Impressions-Improvement
(CGI-I) scale.
Secondary outcome
measures were changes in
behavior or
development noted on the
Aberrant Behavior
Checklist (ABC),
the Behavior Assessment
Scale for Children (BASC),
and the Child
Development Inventory
(CDI)
The DHA group was not rated as improved in
core symptoms of autism compared to the
placebo group on the CGI-I.
Parents (but not teachers) provided a higher
average rating of social skills on the BASC for
the children in the placebo group compared to
the DHA group
Teachers (but not parents)
provided a higher average rating of functional
communication on the
BASC for the children in the DHA group
compared to the placebo group
[73] 13
240 mg of ARA-enriched triglyceride
(40 mg/capsule each of ARA and DHA,
and 0.16 mg/capsule of astaxanthin).
The usual daily doses of this capsule
were 6 capsules (240 mg). The placebo
was an identical capsule containing
olive oil.
16
The outcome measures
were the Social
Responsiveness Scale and
the Aberrant Behavior
Checklist-Community.
This supplementation regimen significantly
improved Aberrant Behavior
Checklist-Community-measured social
withdrawal and Social Responsiveness
Scale-measured communication.
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2.3. Omega-3 in ADHD
The association between ADHD symptoms and low blood levels of ω-3 PUFAs represents a
consistent finding among observational studies. Driven by this evidence, several intervention studies
have been carried out in the last 15 years to evaluate possible beneficial effects ofω-3 PUFAs in the
treatment of behavioral and cognitive symptoms of children with ADHD. Our aim was to review
current evidence from RCTs investigating the efficacy of ω-3 PUFAs supplementation on ADHD
symptomatology. The main characteristics of the 25 RCTs on ADHD included in this review are shown
in Table 1. The majority of studies (n = 17) employed ω-3 PUFAs as monotherapy, whereas eight
studies usedω-3 PUFAs as an adjunctive therapy to methylphenidate (MPH) or atomoxetine (ATMX).
Sample age ranged from 4 [75] to 18 [76] years. Among studies, different ω-3 PUFAs compositions
were used as supplementation: EPA or DHA alone [72,77], EPA with DHA [75,78–87], EPA combined
with DHA and other ω-3 PUFAs orω-3 PUFAs [76,88–94], and, finally, short chainω 3-PUFAs [95,96].
Two studies declared to have supplemented withω-3 PUFAs alone [97] or in combination withω-6
PUFA [98], without specifying which type of fatty acid.
Two RCTs were performed supplementing children with ADHD with either DHA or EPA alone,
as add-on therapy. The first study was carried out by Voigt et al. [99], in which placebo or 345 mg/day
of DHA were administered to children with ADHD for four months. In the second study [77],
ADHD children were divided between those receiving EPA (100–400 mg/day), those receiving zinc
supplement and a placebo group. For both studies, no significant difference between groups was found
on any cognitive or behavioral outcome. However, Salehi [77] performed a subgroup analysis only
on children with attention-deficit disorder subtype, revealing a better clinical response on Conners’
Rating Scales over the eight weeks of treatment in EPA group than zinc group.
With regard to RCTs exploring the effect of combined EPA and DHA at different dose levels,
11 studies have been identified. Among them, six reported some improvement in ADHD symptoms,
whereas the other five studies did not find any significant ameliorating effect.
In a recent RCT [75], 50 children with ADHD were randomized to receive ATMX or ATMX and
ω-3 PUFAs (180 mg EPA, 120 mg DHA) for four months. Supplementation withω-3 PUFAs brought
a reduction of symptoms assessed via Conners’ Parent Rating Scale (CPRS), but at a non-significant
level. However, children with combined type of ADHD showed a statistically significant improvement
over four months compared to the other two types (inattentive and hyperactive). Behdani et al. [78]
investigated whether ω-3 PUFAs treatment (360 mg/day EPA, 240 mg/day DHA) could enhance
therapeutic effects of methylphenidate (MPH) in 69 children with ADHD. After eight weeks
of treatment, both the study group—supplemented with omega-3 plus MPH—and the control
group—supplemented with placebo plus MPH—showed significant reductions in ADHD rating
scale (ADHD-RS) scores, but there was no significant difference between two groups. Similar results
were observed by Bélanger and colleagues [80] in their cross-over RCT, in which they administered
as monotherapy eitherω-3 PUFAs (20–25 mg/kg/day EPA, 8.5–10.5 mg/kg/day DHA) or placebo
to 26 children for eight weeks. They observed a statistically significant amelioration in several CPRS
subscales in both groups, however, treatment group showed greater but not statistically significant
improvement in comparison with placebo group. Milte et al. [84,85] decided to compare, in the context
of a 12-month randomized, controlled, three-way crossover trial, EPA- versus DHA-rich supplements,
using LA-rich oil as placebo. Eighty-seven children with ADHD symptoms were divided in three
groups, each receiving DHA-rich oil, EPA-rich oil and LA-rich oil for four months each. Results showed
no significant treatment effects on cognitive/behavioral variables; however, significant associations
were found between increased blood levels of DHA + EPA and improved literacy, attention and
parent-rated behavior on CPRS.
Focusing on the six trials of DHA + EPA supplementation reporting improvement on ADHD
symptoms, they all choose a minimum duration of 12 weeks and a minimum sample size of 40.
Recently, Bos et al. [79] found a specific effect of DHA + EPA (administered in equal doses of 650 mg)
on parent-rated attention problems over placebo on 40 children with ADHD following 16 weeks
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of treatment. This result is in agreement with a previous RCT of Gustafsson et al. [81], where
supplementation with 500 mg/day of EPA and 2.7 mg/day of DHA improved inattentive problems
but not hyperactive behavior. Kean et al. [82] also reported improvement on several CPRS subscales
in children displaying high levels of inattention and not in those with high hyperactivity. Results in
favor of a treatment effect on other core symptoms of ADHD comes from Manor et al. [83], whose
trial—conducted on 147 ADHD children—showed a significant reduction of parent-rated restlessness
and impulsiveness as rated by parents in the EPA + DHA group compared to placebo. Concerning
neuropsychological functioning, three RCTs using higher doses of EPA than DHA [82,86,87] found a
treatment effect on visual sustained attention performance, delayed memory and working memory
function. Another RCT, conducted by Sinn et al. [94] used a slightly different supplement composition
i.e., the addition of GLA (γ-linolenic acid, omega-6) to EPA and DHA, and also found a significant
improvement in the treatment group compared to placebo on a cognitive measure, which is the ability to
switch and control attention. This latter study belongs to that group of RCTs using EPA, DHA and other
ω-3 PUFAs orω-6 PUFAs as supplementation; beside it, four other studies have shown some beneficial
effects on ADHD symptoms, whereas three studies did not. Sinn et al. [93], using the same sample and
fatty acid composition of the above-mentioned study, observed a significant improvement in the PUFA
group than placebo on all core ADHD symptoms—inattention, hyperactivity/impulsivity—as rated
by parents. Stevens et al. [92] chose to administer to treatment group (n = 25) higher doses of DHA
than EPA (480 and 80 mg, respectively) with the addition of AA (40 mg) and GLA (96 mg) compared
with a placebo (n = 25). For attention problems rated by teachers and for conduct problems rated by
parents, PUFA showed a small but significant effect over placebo whereas no treatment effect was
found on neuropsychological measures (continuous performance test and other tests on short-term
memory, processing speed, auditory processing and visual processing). Hariri et al. [90], in a sample
of 103 children with ADHD under stimulant medication, compared the efficacy of 635 mg/day of
EPA, 195 mg/day DHA and 100 mg/day of other omega-3 fatty acids versus placebo and observed
a significant improvement on Conners’ Abbreviated Questionnaire (ASQ-P) after eight weeks for
supplemented patients but not for those in the placebo group. Johnson et al. [76] randomized
64 ADHD children to receive for 12 weeks either 558 mg/day EPA, 174 mg/day DHA and 60 mg/day
GLA or placebo. Despite finding significant greater improvement on symptom severity and functional
impairment (measured by Clinical Global Impression severity scale) in the supplemented than in
the placebo group, authors considered their RCT an “essentially negative study”, as only 26% of
supplemented children responded to treatment with more than 25% improvement of ADHD symptoms
on ADHD-RS.
Two recent studies [87,88] tested the efficacy of DHA + EPA + ω-6 PUFA with MPH over
MPH monotherapy and came to similar negative results. Barragán et al. [89] used a fatty acid
supplementation that contained a higher ratio of EPA (558 mg/day) than DHA (174 mg/day) and
some GLA (60 mg/day); on the contrary, Assareh et al. [88] used a higher ratio of DHA (241 mg/day)
than EPA (33 mg/day), together with 180 mg/dayω-6 PUFA. Barragán et al. [89] observed a decreasing
in ADHD symptoms in all treatment arms, with no superior effect of PUFA + MPH as compared to
MPH monotherapy on ADHD symptoms. However, the combination of PUFA + MPH lowered the
frequency of adverse events than MPH alone and appeared to be more effective than PUFA alone
for hyperactivity/impulsivity, whereas results on inattention were similar. Even Assareh, despite
finding in their RCT a significant improvement of core ADHD symptoms within both treatment
and control group after 10 weeks, reported no statistical superiority of MPH + PUFA compared
with MPH + placebo. Lastly, negative results come also from Matsudaira and coworkers’ study [91],
in which they did not find any significant ameliorating effect of EPA + DHA + GLA supplementation
(respectively, 558, 174 and 60 mg/day) compared to placebo on ADHD symptoms over 12 weeks.
As mentioned above, two RCTs have supplemented withω-3 PUFAs alone [97] or in combination
with ω-6 [98], without specifying which type of fatty acid. Dashti et al. [97] divided 85 children
with ADHD into three groups: those receivingω-3 PUFAs, those receiving MPH and those receiving
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placebo. They reported a statistically significant improvement of ADHD symptoms for children
in the ω-3 PUFAs group or in the MPH group but not for children in the placebo group after
4 weeks. Perera et al. [98] compared the effect of ω-3 PUFAs (592,74 mg/day) + ω-6 PUFAs
(361.5 mg/day) treatment versus placebo in 94 children with ADHD taking MPH. They reported
significant improvement in the active group compared to placebo after six months in symptoms of
restlessness, inattention and impulsiveness, but they did not measure them with standardized tools.
Finally, Raz et al. [96] and Dubnov-Raz et al. [95] supplemented children with short chain fatty
acids (respectively, ALA or a combination of higher LA and ALA) and they both reported no significant
beneficial effect for any of the variables examined.
3. Conclusions and Future Directions
The aim of this review was to provide a comprehensive overview of the effects ofω-3 PUFAs in
three major neuropsychiatric disorders: psychosis, ASD, and ADHD (Table 2). The interest on these
illnesses raised from the evidence suggesting that the onset of these disorders arise during the human
brain development in which ω-3 PUFAs play a central role [100]. Indeed, it has been reported that
DHA exerts several functions in process of neurogenesis, neurotransmission and protection against
oxidative stress [101,102] and it starts to accumulate in brain during pregnancy, especially in the
second half of gestation [103–105], coinciding with the growth spurt in the grey matter [105]. Several
theories have been proposed to explain why deficits and imbalances ofω-3 PUFAs can be linked to
impairments in cognitive and behavioral performances [101,106]. Therefore, in the last decade, we
found a growing number of randomized controlled trials (RCT) testing the efficacy of ω-3 PUFAs
alone or as add-on therapy in the treatment of different psychiatric disorders. However, the available
evidence is not always in agreement, probably due to the heterogeneity of the methods employed
by the original studies, which often had small and not homogeneous sample size, different selection
criteria, different subtypes and dosage of ω-3 PUFAs (e.g., EPA, DHA, a combination of the two,
or the addition of omega-6 PUFAs) as well as various duration of supplementation. Another relevant
limiting methodological point is represented by the multitask nature of the neuropsychological tests
and scales, leading to results unavoidably biased without adjusting for multiple tests—and in this case,
a significant result may hardly exist.
Table 2. Effects ofω-3 PUFAs supplementation in psychosis, ADHD, ASD: summary.
Diagnosis Positive Results Negative Results Positive Results WithoutStatistical Significance
Ultra Hight Risk
Psychosis [46,51] [50]
First psychosis episode [54] [55]
ADHD [76,79,81,83,86,90,98] [84,85,87,91,95,99] [75,77,78,80,88,89,92,96,97]
Elevated ADHD
symptoms [93,94] [82]
Autism [73] [72] [71]
Despite these limitations, overall, the results seem to highlight the beneficial role ofω-3 PUFAs in
the three neuropsychiatric disorders described above. Specifically, for psychotic patients, it has been
reported thatω-3 PUFAs supplementation could be effective in preventing transition to psychosis and
in the treatment of severity symptoms and global functioning.
Furthermore, the available evidence also suggests that the detection and treatment ofω-3 PUFAs
deficiency early in the course of illness may be required to exert the greatest protection against transition
to psychosis and severity of symptoms. However, this hypothesis requires future investigations.
With regard to ADHD, the effect of ω-3 PUFAs supplementation has been widely studied in
this disorder via RCTs. However, also in this case, the great methodological heterogeneity across
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studies, including variations in sample size, study duration, type and dosage of supplementation,
makes difficult to compare the findings and draw firm conclusions about the efficacy. We found 13 out
of 25 studies reporting some beneficial effect ofω-3 PUFAs on ADHD symptoms, whereas the other
12 found negative results. A common characteristic shared by RCTs reporting positive outcomes is
that they all have—in tandem or alone—a minimum sample size of 50 and minimum study duration
of 15 weeks. In terms of supplementation, they involve both EPA and DHA, except for two studies
whose ω-3 PUFAs composition is not declared. Studies that add GLA to EPA and DHA were more
likely to obtain positive than negative outcomes. On the other hand, looking at studies reporting
negative outcomes, they follow a different methodology compared to positive studies, including the
use of small sample sizes, short study duration (less than 15 weeks), supplementations with either
DHA or EPA alone, the lack of a placebo arm. An exception is represented by Milte and coworkers’
study [84], which has sample size, type of supplementation and study duration comparable to that of
other studies with positive results, but failed to find a significant treatment effect of EPA or DHA over
placebo. Authors attributed the negative finding to the sample size, considered too small compared
with that required to provide sufficient power to detect a significant treatment effect.
Moreover, considering the eight studies exploring the effect ofω-3 PUFAs as an add-on therapy
to MPH or ATX, six failed to find a better outcome for combined treatment versus pharmacotherapy
alone, whereas only two observed a greater improvement in the combined treatment group. However,
as described above, negative studies—more than positive ones—have several weaknesses that could
have affected the results so that it is still premature to draw conclusions about the appropriateness
of combined treatment for ADHD. Interestingly, Barragán et al. [89], despite finding no increased
benefit on symptoms of combined ω-3/ω-6 PUFAs and MPH over MPH monotherapy, observed
that children receiving combined treatment needed lower doses of MPH to achieve the same clinical
improvement of those receiving MPH alone and had a lower rate of withdrawal and a lower incidence
of adverse events.
What has frequently emerged from recent meta-analyses [29,107–109] is a small but significant
effect ofω-3 PUFAs in ADHD composite symptoms that is considered, on one hand, too modest to
recommend ω-3 PUFAs in lieu of existing pharmacotherapies, whereas on the other hand, enough
reliable to justify the use ofω-3 PUFAs as coadjutors of pharmacologic treatments, given their better
tolerability in terms of side effects. More high-quality RCTs are encouraged in order to clarify the
effectiveness ofω-3 PUFAs supplementation in children and adolescents with ADHD. Future studies
should use primarily both EPA and DHA within double-blind designs, recruit samples of adequate
sizes and provide supplementation for at least six months [109] to support fatty acid turnover in the
brain, which is thought to be quite low especially in 6–12-year-old children [110]. Hopefully, more
reliable investigation techniques are welcome to prevent the dispersion typical of multitask scales and
multiple tests, whose use leads to the unavoidable loss of statistical power, whichever the study design
and sample size.
Finally, regardingω-3 PUFAs and ASD, the limited evidence available is insufficient for drawing
any conclusion. The trials included in this review varied in their durations, sample size and amounts of
ω-3 PUFAs supplementation, therefore there is still uncertainty about the effects of these fatty acids on
symptoms of ASD in children. In particular the three RCTs included have different duration (six weeks,
six months and 16 weeks), while ω-3 PUFAs erythrocyte membranes may reach a steady state after six
months and at least four months is needed to demonstrate an effect on cognitive performance. Even
longer study periods of one year might be needed to demonstrate behavioral changes in response to
ω-3 PUFAs supplementation [70].
Given the importance of DHA in brain function and development, and its possible implications in
the modulation of ASD symptoms, it is important to continue to investigate the positive effects
of the supplementation. In this population, the dietary intake of ω-3 PUFAs rich foods is low
due to a monotonous dietary pattern: the incorporation of DHA into cellular membranes may be
therefore insufficient.
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In conclusion, the lack of consistency across studies that have explored theω-3 PUFAs effects in
these major neurodevelopmental disorders implies the necessity of larger prospective interventional
clinical studies, with intervention starting at the beginning of illness, utilizing therapeutic dosage of
ω-3 PUFAs, and new methodologies of investigation. Despite all the uncertainties that have been
mentioned, we do believe that this is an exciting area for future scientific studies since it will help
elucidate the critical role played by ω-3 PUFAs in human brain development with wide-reaching
implications in health and disease.
4. Material and Methods
A comprehensive search on PUBMED of all RCTs using ω-3 PUFAs on patients with autism,
ADHD and psychotic symptoms published up to August 2017 was performed. Articles of potential
interest were identified by using the following search terms: “omega-3“, ”polyunsaturated fatty acids”,
“PUFAs”, “trial”, “EPA”, “DHA”, “docosahexaenoic acids”, “eicosapentaenoic acids” combined
with the following term: “autism”, “neurodevelopmental spectrum disorder”, “attention deficit
hyperactivity disorder”, “adhd”, “psychosis”, “psychotic disorder” or “psychotic symptom” or
“first psychotic episode”, “ultrarisk psychosis”, “risk psychosis”. In this review, RCTs examining
the efficacy of ω-3 PUFAs in young adults, adolescents and children with autism, ADHD and
psychotic symptoms were selected. Trials were included if they examined the efficacy ofω-3 PUFAs to
target autism, ADHD and psychotic symptoms as a primary outcome and in case they investigated
the efficacy of ω-3 PUFAs in transition to psychosis status in the context of subjects with risk or
ultra-risk for psychotic disorder. We included also subjects at risk for ADHD if the authors used
validated rating scales to measure the presence and severity of ADHD symptoms as a primary
outcome. We considered only trials in which the authors used an exposure ofω-3 PUFAs as a unique
treatment or as an adjunctive therapy to other drugs (e.g., antipsychotics, stimulants), or other no
pharmacological strategies such as psychotherapy, vitamin and mineral supplements compared to
placebo or pharmacotherapy alone.
To limit the heterogeneity of this review and to reduce selection biases, we decided to exclude:
trials examining the efficacy ofω-3 PUFAs in treating psychotic symptoms in subjects with diagnosis
of chronic schizophrenia; trials examining the efficacy ofω-3 PUFAs in treating ADHD symptoms in
subjects with diagnoses different from ADHD (e.g., dyslexia, developmental coordination disorder);
trials involving healthy subjects; trials analyzing levels of ω-3 PUFAs; studies that not explore the
effects of ω-3 PUFAs on autism, ADHD and psychotic symptoms as primary outcome. In addition,
we excluded trials that employed diet enriched of ω-3 PUFAs as a supplementation. Among the
384 articles retrieved, 116 RCT studies were identified and screened by reading the abstract and, when
necessary, the full text, in order to select those articles relevant for the analysis. A manual search
of bibliographic cross-referencing complemented the search. Reference lists of relevant papers were
also inspected to identify any additional trials. Relevant articles were obtained and included in the
review if they used an exposure ofω-3 PUFAs, included autism, ADHD and psychotic symptoms as
an outcome measure, enrolled human participants, included a comparison group, and reported a trial.
The process of identification and inclusion of trials is summarized in Figures 1–3. Finally, 33 trials
were included for the review. All searches, trial identification, data abstraction, and tabulation were
completed independently by 2 researchers. Discordances were discussed and resolved.
Int. J. Mol. Sci. 2017, 18, 2608 18 of 25
Int. J. Mol. Sci. 2017, 17, 2608 15 of 23 
 
strategies such as psychotherapy, vitamin and mineral supplements compared to placebo or 
pharmacotherapy alone. 
To limit the heterogeneity of this review and to reduce selection biases, we decided to exclude: 
trials examining the efficacy of ω-3 PUFAs in treating psychotic symptoms in subjects with diagnosis 
of chronic schizophrenia; trials examining the efficacy of ω-3 PUFAs in treating ADHD symptoms in 
subjects with diagnoses different from ADHD (e.g., dyslexia, developmental coordination disorder); 
trials involving healthy subjects; trials analyzing levels of ω-3 PUFAs; studies that not explore the 
effects of ω-3 PUFAs on autism, ADHD and psychotic symptoms as primary outcome. In addition, 
we excluded trials that employed diet enriched of ω-3 PUFAs as a supplementation. Among the 384 
articles retrieved, 116 RCT studies were identified and screened by reading the abstract and, when 
necessary, the full text, in order to select those articles relevant for the analysis. A manual search of 
bibliographic cross-referencing complemented the search. Reference lists of relevant papers were also 
inspected to identify any additional trials. Relevant articles were obtained and included in the review 
if they used an exposure of ω-3 PUFAs, included autism, ADHD and psychotic symptoms as an 
outcome measure, enrolled human participants, included a comparison group, and reported a trial. 
The process of identification and inclusion of trials is summarized in Figures 1–3. Finally, 33 trials 
were included for the review. All searches, trial identification, data abstraction, and tabulation were 
completed independently by 2 researchers. Discordances were discussed and resolved. 
 
Figure 1. PRISMA diagram: ω-3 PUFAs supplementation in early psychotic symptoms. 
Figure 1. PRISMA diagram: ω-3 PUFAs supplementation in early psychotic symptoms.Int. J. Mol. Sci. 2017, 17, 2608 16 of 23 
 
 
Figure 2. PRISMA diagram: ω-3 PUFAs supplementation in ADHD. 
 
Figure 3. PRISMA diagram: ω-3 PUFAs supplementation in ASD. 
Figure 2. PRISMA diagram: ω-3 PUFAs supplementation in ADHD.
Int. J. Mol. Sci. 2017, 18, 2608 19 of 25
Int. J. Mol. Sci. 2017, 17, 2608 16 of 23 
 
 
Figure 2. PRISMA diagram: ω-3 PUFAs supplementation in ADHD. 
 
Figure 3. PRISMA diagram: ω-3 PUFAs supplementation in ASD. Figure 3. PRIS diagra : -3 P F s supple entation in S .
Acknowledgments: Supported by contributions from the Italian Ministry of Health (IRCCS grant)
(RF-2011-02352308).
Author Contributions: All authors conceived this review and agreed to the manuscript in its current form.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Baxter, A.J.; Patton, G.; Scott, K.M.; Kate, M.; Degenhardt, L.; Whiteford, H.A. Global Epidemiology of
Mental Disorders: What Are We Missing? PLoS ONE 2013, 8, e65514. [CrossRef] [PubMed]
2. Logan, A.C.; Jacka, F.N. Nutritional psychiatry research: An emerging discipline and its intersection with
global urbanization, environmental challenges and the evolutionary mismatch. J. Phys. Anthropol. 2014, 33, 22.
[CrossRef] [PubMed]
3. McNamara, R.K.; Vannest, J.J.; Valentine, C.J. Role of perinatal long-chain omega-3 fatty acids in cortical
circuit maturation: Mechanisms and implications for psychopathology. World J. Psychiatry 2015, 5, 15–34.
[CrossRef] [PubMed]
4. Innis, S.M. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty acids. J. Pediatr. 2003,
143, S1–S8. [CrossRef]
5. Kiecolt-Glaser, J.K.; Preacher, K.J.; MacCallum, R.C.; Atkinson, C.; Malarkey, W.; Glaser, R. Chronic stress and
age-related increases in the proinflammatory cytokine IL-6. Proc. Natl. Acad. Sci. USA 2003, 100, 9090–9095.
[CrossRef] [PubMed]
6. Das, U.N. Biological significance of essential fatty acids. J. Assoc. Phys. India 2006, 54, 309–319.
7. Lauritzen, L.; Brambilla, P.; Mazzocchi, A.; Harsløf, L.; Ciappolino, V.; Agostoni, C. DHA Effects in Brain
Development and Function. Nutrients 2016, 8, 6. [CrossRef] [PubMed]
8. Carver, J.D.; Benford, V.J.; Han, B.; Cantor, A.B. The relationship between age and the fatty acid composition
of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 2001, 56, 79–85. [CrossRef]
Int. J. Mol. Sci. 2017, 18, 2608 20 of 25
9. Herrera, E. Implications of dietary fatty acids during pregnancy on placental, fetal and postnatal
development—A review. Placenta 2002, 23 (Suppl. A), S9–S19. [CrossRef] [PubMed]
10. Jørgensen, M.H.; Nielsen, P.K.; Michaelsen, K.; Lund, P.; Lauritzen, L. The composition of polyunsaturated
fatty acids in erythrocytes of lactating mothers and their infants. Matern. Child Nutr. 2006, 2, 29–39. [CrossRef]
[PubMed]
11. European Food Safety Authority. The Panel on Dietetic Products, Nutrition and Allergies on a re-quest from
Mead Johnson Nutritionals. Scientific opinion on DHA and ARA and visual development. EFSA J. 2009,
941, 1–14.
12. Browning, L.M.; Walker, C.G.; Mander, A.P.; West, A.; Madden, J.; Gambell, J.; Young, S.; Wang, L.; Jebb, S.;
Calder, P. Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as
supplements providing doses equivalent to typical intakes of oily fish. Am. J. Clin. Nutr. 2012, 96, 748–758.
[CrossRef] [PubMed]
13. Mischoulon, D.; Freeman, M.P. Omega-3 fatty acids in psychiatry. Psychiatr. Clin. N. Am. 2013, 36, 15–23.
[CrossRef] [PubMed]
14. Ross, B.M.; Seguin, J.; Sieswerda, L.E. Omega-3 fatty acids as treatments for mental illness: Which disorder
and which fatty acid? Lipids Health Dis. 2007, 6, 21. [CrossRef] [PubMed]
15. Hallahan, B.; Garland, M.R. Essential fatty acids and mental health. Br. J. Psychiatry 2005, 186, 275–277.
[CrossRef] [PubMed]
16. Assisi, A.; Banzi, R.; Buonocore, C.; Capasso, F.; Muzio, V.D.; Michelacci, F.; Renzo, D.; Tafuri, G.; Trotta, F.;
Vitocolonna, M.; et al. Fish oil and mental health: The role of n-3 long-chain polyunsaturated fatty acids in
cognitive development and neurological disorders. Int. Clin. Psychopharmacol. 2006, 21, 319–336. [CrossRef]
[PubMed]
17. De la Presa Owens, S.; Innis, S.M. Docosahexaenoic and arachidonic acid prevent a decrease in dopaminergic
and serotoninergic neurotransmitters in frontal cortex caused by a linoleic and α-linolenic acid deficient diet
in formula-fed piglets. J. Nutr. 1999, 129, 2088–2093. [PubMed]
18. Galli, C.; Trzeciak, H.I.; Paoletti, R. Effects of essential fatty acid deficiency on myelin and various subcellular
structures in rat brain. J. Neurochem. 1972, 19, 1863–1867. [CrossRef] [PubMed]
19. Yehuda, S.; Rabinovitz, S.; Carasso, R.L.; Mostofsky, D.I. The role of polyunsaturated fatty acids in restoring
the aging neuronal membrane. Neurobiol. Aging 2002, 23, 843–853. [CrossRef]
20. Haag, M. Essential Fatty Acids and the Brain. Can. J. Psychiatry 2003, 48, 195–203. [CrossRef] [PubMed]
21. Colangelo, L.A.; He, K.; Whooley, M.A.; Daviglus, M.; Liu, K. Higher dietary intake of long-chain ω-3
polyunsaturated fatty acids is inversely associated with depressive symptoms in women. Nutrition 2009, 25,
1011–1019. [CrossRef] [PubMed]
22. Sinn, N.; Milte, C.; Howe, P.R.C. Oiling the brain: A review of randomized controlled trials of omega-3 fatty
acids in psychopathology across the lifespan. Nutrients 2010, 2, 128–170. [CrossRef] [PubMed]
23. Sinclair, A.J.; Begg, D.; Mathai, M.; Weisinger, R.S. Omega 3 fatty acids and the brain: Review of studies in
depression. Asia Pac. J. Clin. Nutr. 2007, 16 (Suppl. S1), 391–397. [PubMed]
24. McNamara, R.K.; Jandacek, R.; Rider, T.; Tso, P.; Hahn, C.; Richtand, N.; Stanford, K. Abnormalities in the
fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: Gender differences
and partial normalization with antipsychotic medications. Schizophr. Res. 2007, 91, 37–50. [CrossRef]
[PubMed]
25. Khan, M.M.; Evans, D.R.; Gunna, V.; Scheffer, R.; Parikh, V.; Mahadik, S. Reduced erythrocyte membrane
essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of
psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58, 1–10. [CrossRef]
26. Reddy, R.D.; Keshavan, M.S.; Yao, J.K. Reduced red blood cell membrane essential polyunsaturated fatty
acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30, 901–911.
[CrossRef] [PubMed]
27. Hoen, W.P.; Lijmer, J.G.; Duran, M.; Wanders, R.; van Beveren, N.; de Haan, L. Red blood cell polyunsaturated
fatty acids measured in red blood cells and schizophrenia: A meta-analysis. Psychiatry Res. 2013, 207, 1–12.
[CrossRef] [PubMed]
28. Sliwinski, S.; Croonenberghs, J.; Christophe, A.; Deboutte, D.; Maes, M. Polyunsaturated fatty acids: Do they
have a role in the pathophysiology of autism? Neuro Endocrinol. Lett. 2006, 27, 465–471. [PubMed]
Int. J. Mol. Sci. 2017, 18, 2608 21 of 25
29. Hawkey, E.; Nigg, J.T. Omega-3 fatty acid and ADHD: Blood level analysis and meta-analytic extension of
supplementation trials. Clin. Psychol. Rev. 2014, 34, 496–505. [CrossRef] [PubMed]
30. Tesei, A.; Crippa, A.; Ceccarelli, S.B.; Mauri, M.; Molteni, M.; Agostoni, C.; Nobile, M. The potential relevance
of docosahexaenoic acid and eicosapentaenoic acid to the etiopathogenesis of childhood neuropsychiatric
disorders. Eur. Child Adolesc. Psychiatry 2016, 26, 1011–1030. [CrossRef] [PubMed]
31. Colter, A.L.; Cutler, C.; Meckling, K.A. Fatty acid status and behavioural symptoms of Attention Deficit
Hyperactivity Disorder in adolescents: A case-control study. Nutr. J. 2008, 7, 8. [CrossRef] [PubMed]
32. Crippa, A.; Agostoni, C.; Mauri, M.; Mauri, M.; Molteni, M.; Nobile, M. Polyunsaturated Fatty Acids Are
Associated with Behavior but Not with Cognition in Children with and without ADHD: An Italian study.
J. Atten. Disord. 2016. [CrossRef] [PubMed]
33. Stevens, L.J.; Zentall, S.S.; Deck, J.L.; Abate, M.; Watkins, B.; Lipp, S.; Burgess, J. Essential fatty acid
metabolism in boys with attention-deficit hyperactivity disorder. Am. J. Clin. Nutr. 1995, 62, 761–768.
[PubMed]
34. Mueser, K.T.; McGurk, S.R. Schizophrenia. Lancet 2004, 363, 2063–2072. [CrossRef]
35. Whiteford, H.A.; Degenhardt, L.; Rehm, J.; Baxter, A.; Ferrari, A.; Erskine, H.; Charlson, F.; Norman, R.;
Flaxman, A.; Johns, N.; et al. Global burden of disease attributable to mental and substance use disorders:
Findings from the Global Burden of Disease Study 2010. Lancet 2013, 382, 1575–1586. [CrossRef]
36. Van Os, J.; Linscott, R.J.; Myin-Germeys, I.; Delespaul, P.; Krabbendam, L. A systematic review and
meta-analysis of the psychosis continuum: Evidence for a psychosis proneness-persistence-impairment
model of psychotic disorder. Psychol. Med. 2009, 39, 179–195. [CrossRef] [PubMed]
37. McGlashan, T.H. Commentary: Progress, issues, and implications of prodromal research: An inside view.
Schizophr. Bull. 2003, 29, 851–858. [CrossRef] [PubMed]
38. Ruhrmann, S.; Schultze-Lutter, F.; Salokangas, R.K.R.; Heinimaa, M.; Linszen, D.; Dingemans, P.;
Birchwood, M.; Patterson, P.; Juckel, G.; Heinz, A.; et al. Prediction of psychosis in adolescents and young
adults at high risk: Results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry
2010, 67, 241–251. [CrossRef] [PubMed]
39. Yung, A.R.; Phillips, L.J.; Yuen, H.P.; Francey, S.; McFarlane, C.; Hallgren, M.; McGorry, P. Psychosis
prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr. Res. 2003, 60, 21–32.
[CrossRef]
40. Miller, T.J.; McGlashan, T.H.; Rosen, J.L.; Somjee, L.; Markovich, P.; Stein, K.; Woods, S. Prospective diagnosis
of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes:
Preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 2002, 159, 863–865.
[CrossRef] [PubMed]
41. Fusar-Poli, P. Prodromal psychosis: Diagnosis and treatment. Curr. Pharm. Des. 2012, 18, 337. [CrossRef]
[PubMed]
42. Stafford, M.R.; Jackson, H.; Mayo-Wilson, E.; Morrison, A.; Kendall, T. Early interventions to prevent
psychosis: Systematic review and meta-analysis. BMJ 2013, 346, f185. [CrossRef] [PubMed]
43. Evans, D.R.; Parikh V, V.; Khan, M.M.; Coussons, C.; Buckley, P.; Mahadik, S. Red blood cell membrane
essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment.
Prostaglandins Leukot. Essent. Fat. Acids 2003, 69, 393–399. [CrossRef]
44. Glen, A.I.; Glen, E.M.; Horrobin, D.F.; Vaddadi, K.; Spellman, M.; Morse-Fisher, N.; Ellis, K.; Skinner, F.
A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases.
Schizophr. Res. 1994, 12, 53–61. [CrossRef]
45. Horrobin, D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental
concept of schizophrenia. Schizophr. Res. 1998, 30, 193–208. [CrossRef]
46. Amminger, G.P.; Schäfer, M.R.; Papageorgiou, K.; Klier, C.; Cotton, S.; Harrigan, S.; Mackinnon, A.;
McGorry, P.; Berger, G. Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders.
Arch. Gen. Psychiatry 2010, 67, 146–154. [CrossRef] [PubMed]
47. Emsley, R.; Myburgh, C.; Oosthuizen, P.; van Rensburg, S.J. Randomized, placebo-controlled study of
ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159,
1596–1598. [CrossRef] [PubMed]
48. Mellor, J.E.; Laugharne, J.D.; Peet, M. Schizophrenic symptoms and dietary intake of n-3 fatty acids.
Schizophr. Res. 1995, 18, 85–86. [CrossRef]
Int. J. Mol. Sci. 2017, 18, 2608 22 of 25
49. Schlögelhofer, M.; Amminger, G.P.; Schaefer, M.R.; Fusar-Poli, P.; Smesny, S.; Mcgorry, P.; Berger, G.;
Mossaheb, N. Polyunsaturated fatty acids in emerging psychosis: A safer alternative? Early Interv. Psychiatry
2014, 8, 199–208. [CrossRef] [PubMed]
50. McGorry, P.D.; Nelson, B.; Markulev, C.; Yuen, H.; Schäfer, M.; Mossaheb, N.; Schlögelhofer, M.; Smesny, S.;
Hickie, I.; Berger, G. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for
Psychotic Disorders. JAMA Psychiatry 2017, 74, 19. [CrossRef] [PubMed]
51. Amminger, G.P.; Chanen, A.M.; Ohmann, S.; Klier, C.M.; Mossaheb, N.; Bechdolf, A.; Nelson, B.;
Thompson, A.; McGorry, P.D.; Yung, A.R.; et al. Omega-3 Fatty Acid Supplementation in Adolescents
with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup
Analysis of a Double-Blind, Randomized Controlled Trial. Can. J. Psychiatry 2013, 58, 402–408. [CrossRef]
[PubMed]
52. Amminger, G.P.; Schäfer, M.R.; Schlögelhofer, M.; Klier, C.; McGorry, P. Longer-term outcome in the
prevention of psychotic disorders by the Vienna omega-3 study. Nat. Commun. 2015, 6, 7934. [CrossRef]
[PubMed]
53. Smesny, S.; Milleit, B.; Hipler, U.-C.; Milleit, C.; Schäfer, M.; Klier, C.; Holub, M.; Holzer, I.; Berger, G.;
Otto, M.; Nenadic, I. Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity
and membrane fatty acid profiles in individuals at ultra-high risk for psychosis. Mol. Psychiatry 2014, 19,
317–324. [CrossRef] [PubMed]
54. Pawełczyk, T.; Grancow-Grabka, M.; Kotlicka-Antczak, M.; Trafalska, E.; Pawełczyk, A. A randomized
controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3
polyunsaturated fatty acids in first episode schizophrenia. J. Psychiatr. Res. 2016, 73, 34–44. [CrossRef]
[PubMed]
55. Berger, G.E.; Proffitt, T.-M.; McConchie, M.; Yuen, H.; Wood, S.; Amminger, G.; Brewer, W.;
McGorry, P. Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled
trial. J. Clin. Psychiatry 2007, 68, 1867–1875. [CrossRef] [PubMed]
56. Berger, G.E.; Wood, S.J.; Wellard, R.M.; Proffitt, T.; McConchie, M.; Amminger, G.; Jackson, G.; Velakoulis, D.;
Pantelis, C.; McGorry, P. Ethyl-Eicosapentaenoic Acid in First-Episode Psychosis. A 1H-MRS Study.
Neuropsychopharmacology 2008, 33, 2467–2473. [CrossRef] [PubMed]
57. Nakamura, K.; Wang, W.; Kang, U.J. The role of glutathione in dopaminergic neuronal survival. J. Neurochem.
1997, 69, 1850–1858. [CrossRef] [PubMed]
58. Dringen, R. Metabolism and functions of glutathione in brain. Prog. Neurobiol. 2000, 62, 649–671. [CrossRef]
59. Irving, C.B.; Mumby-Croft, R.; Joy, L.A. Polyunsaturated fatty acid supplementation for schizophrenia.
In The Cochrane Database of Systematic Reviews; Irving, C.B., Ed.; John Wiley & Sons, Ltd.: Chichester, UK,
2006; p. CD001257.
60. Freeman, M.P.; Hibbeln, J.R.; Wisner, K.L.; Davis, J.; Mischoulon, D.; Peet, M.; Keck, P.; Marangell, L.;
Richardson, A.; Lake, J.; et al. Omega-3 fatty acids: Evidence basis for treatment and future research in
psychiatry. J. Clin. Psychiatry 2006, 67, 1954–1967. [CrossRef] [PubMed]
61. Fusar-Poli, P.; Berger, G. Eicosapentaenoic Acid Interventions in Schizophrenia. J. Clin. Psychopharmacol.
2012, 32, 179–185. [CrossRef] [PubMed]
62. Chen, A.T.; Chibnall, J.T.; Nasrallah, H.A. A meta-analysis of placebo-controlled trials of omega-3 fatty
acid augmentation in schizophrenia: Possible stage-specific effects. Ann. Clin. Psychiatry 2015, 27, 289–296.
[PubMed]
63. Akter, K.; Gallo, D.A.; Martin, S.A.; Myronyuk, N.; Roberts, R.; Stercula, K.; Raffa, R. A review of the possible
role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia.
J. Clin. Pharm. Ther. 2012, 37, 132–139. [CrossRef] [PubMed]
64. Kelly, C.; Hadjinicolaou, A.V.; Holt, C.; Agius, M.; Zaman, R. Meta-analysis of medical and non-medical
treatments of the prodromal phase of psychotic illness in at-risk mental states. Psychiatr. Danub. 2010, 22
(Suppl. S1), S56–S62. [PubMed]
65. Preti, A.; Cella, M. Randomized-controlled trials in people at ultra high risk of psychosis: A review of
treatment effectiveness. Schizophr. Res. 2010, 123, 30–36. [CrossRef] [PubMed]
66. Souaiby, L.; Gaillard, R.; Krebs, M.-O. Durée de psychose non traitée: État des lieux et analyse critique.
Encephale 2016, 42, 361–366. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2608 23 of 25
67. Marshall, M.; Rathbone, J. Early intervention for psychosis. In The Cochrane Database of Systematic Reviews;
Marshall, M., Ed.; John Wiley & Sons, Ltd.: Chichester, UK, 2011; p. CD004718.
68. Müller, H.; Wießmann, T.; Bechdolf, A. Interventionen bei Personen mit erhöhtem Psychoserisiko: Eine
aktuelle Übersicht über randomisiert kontrollierte Studien. Fortschr. Neurol. Psychiatr. 2012, 80, 570–579.
[CrossRef] [PubMed]
69. Van der Gaag, M.; Smit, F.; Bechdolf, A.; French, P.; Linszen, D.; Yung, A.; McGorry, P.; Cuijpers, P. Preventing
a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and
longer-term follow-ups. Schizophr. Res. 2013, 149, 56–62. [CrossRef] [PubMed]
70. Mazahery, H.; Stonehouse, W.; Delshad, M.; Kruger, M.; Conlon, C.; Beck, K.; von Hurst, P. Relationship
between Long Chain n-3 Polyunsaturated Fatty Acids and Autism Spectrum Disorder: Systematic Review
and Meta-Analysis of Case-Control and Randomised Controlled Trials. Nutrients 2017, 9, 155. [CrossRef]
[PubMed]
71. Bent, S.; Hendren, R.L.; Zandi, T.; Law, K.; Choi, J.; Widjaja, F.; Kalb, L.; Nestle, J.; Law, P. Internet-Based,
Randomized, Controlled Trial of Omega-3 Fatty Acids for Hyperactivity in Autism. J. Am. Acad. Child
Adolesc. Psychiatry 2014, 53, 658–666. [CrossRef] [PubMed]
72. Voigt, R.G.; Mellon, M.W.; Katusic, S.K.; Weaver, A.; Matern, D.; Mellon, B.; Jensen, C.; Barbaresi, W.
A Randomized, Double-Blind, Placebo-Controlled Trial of Dietary Docosahexaenoic Acid (DHA)
Supplementation in Children with Autism. J. Pediatr. Gastroenterol. Nutr. 2013, 58, 1. [CrossRef] [PubMed]
73. Yui, K.; Koshiba, M.; Nakamura, S.; Kobayashi, Y. Effects of Large Doses of Arachidonic Acid Added
to Docosahexaenoic Acid on Social Impairment in Individuals With Autism Spectrum Disorders.
J. Clin. Psychopharmacol. 2012, 32, 200–206. [CrossRef] [PubMed]
74. Horvath, A.; Łukasik, J.; Szajewska, H. ω-3 Fatty Acid Supplementation Does Not Affect Autism Spectrum
Disorder in Children: A Systematic Review and Meta-Analysis. J. Nutr. 2017, 147, 367–376. [CrossRef]
[PubMed]
75. Anand, P.; Sachdeva, A. Effect of Poly Unsaturated Fatty Acids Administration on Children with Attention
Deficit Hyperactivity Disorder: A Randomized Controlled Trial. J. Clin. Diagn. Res. 2016, 10, OC01–OC05.
[CrossRef] [PubMed]
76. Johnson, M.; Ostlund, S.; Fransson, G.; Kadesjö, B.; Gillberg, C. Omega-3/omega-6 fatty acids for
attention deficit hyperactivity disorder: A randomized placebo-controlled trial in children and adolescents.
J. Atten. Disord. 2009, 12, 394–401. [CrossRef] [PubMed]
77. Salehi, B.; Mohammadbeigi, A.; Sheykholeslam, H.; Moshiri, E.; Dorreh, F. Omega-3 and Zinc
supplementation as complementary therapies in children with attention-deficit/hyperactivity disorder.
J. Res. Pharm. Pract. 2016, 5, 22–26. [CrossRef] [PubMed]
78. Behdani, F.; Hebrani, P.; Naseraee, A.; Haghighi, M.; Akhavanrezayat, A. Does omega-3 supplement enhance
the therapeutic results of methylphenidate in attention deficit hyperactivity disorder patients? J. Res. Med. Sci.
2013, 18, 653–658. [PubMed]
79. Bos, D.J.; Oranje, B.; Veerhoek, E.S.; van Diepen, R.; Weusten, J.; Demmelmair, H.; Koletzko, B.; De Sain-Van
Der Velden, M.G.; Eilander, A.; Hoeksma, M.; et al. Reduced Symptoms of Inattention after Dietary
Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder.
Neuropsychopharmacology 2015, 40, 2298–2306. [CrossRef] [PubMed]
80. Bélanger, S.A.; Vanasse, M.; Spahis, S.; Sylvestre, M.; Lippé, S.; L'heureux, F.; Ghadirian, P.; Vanasse, C.;
Levy, E. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: A randomized,
double-blind, placebo-controlled study. Paediatr. Child Health 2009, 14, 89–98. [CrossRef] [PubMed]
81. Gustafsson, P.A.; Birberg-Thornberg, U.; Duchén, K.; Landgren, M.; Malmberg, K.; Pelling, H.; Strandvik, B.;
Karlsson, T. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children
with ADHD. Acta Paediatr. 2010, 99, 1540–1549. [CrossRef] [PubMed]
82. Kean, J.D.; Sarris, J.; Scholey, A.; Silberstein, R.; Downey, L.; Stough, C. Reduced inattention and hyperactivity
and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents
with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): A randomised,
double-blind, placebo-controlled trial. Psychopharmacology 2017, 234, 403–420. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2608 24 of 25
83. Manor, I.; Magen, A.; Keidar, D.; Rosen, S.; Tasker, H.; Cohen, T.; Richter, Y.; Zaaroor-Regev, D.;
Manor, Y.; Weizman, A. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit
hyperactivity disorder symptoms in children: A double-blind placebo-controlled trial, followed by an
open-label extension. Eur. Psychiatry 2012, 27, 335–342. [CrossRef] [PubMed]
84. Milte, C.M.; Parletta, N.; Buckley, J.D.; Buckley, J.; Coates, A.; Young, R.; Howe, P. Increased Erythrocyte
Eicosapentaenoic Acid and Docosahexaenoic Acid Are Associated With Improved Attention and Behavior
in Children With ADHD in a Randomized Controlled Three-Way Crossover Trial. J. Atten. Disord. 2015, 19,
954–964. [CrossRef] [PubMed]
85. Milte, C.M.; Parletta, N.; Buckley, J.D.; Coates, A.; Young, R.; Howe, P. Eicosapentaenoic and docosahexaenoic
acids, cognition, and behavior in children with attention-deficit/hyperactivity disorder: A randomized
controlled trial. Nutrition 2012, 28, 670–677. [CrossRef] [PubMed]
86. Vaisman, N.; Kaysar, N.; Zaruk-Adasha, Y.; Pelled, D.; Brichon, G.; Zwingelstein, G.; Bodennec, J. Correlation
between changes in blood fatty acid composition and visual sustained attention performance in children
with inattention: Effect of dietary n-3 fatty acids containing phospholipids. Am. J. Clin. Nutr. 2008, 87,
1170–1180. [PubMed]
87. Widenhorn-Müller, K.; Schwanda, S.; Scholz, E.; Spitzer, M.; Bode, H. Effect of supplementation
with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention
deficit/hyperactivity disorder (ADHD): A randomized placebo-controlled intervention trial. Prostaglandins
Leukot. Essent. Fat. Acids 2014, 91, 49–60. [CrossRef] [PubMed]
88. Assareh, M.; Davari Ashtiani, R.; Khademi, M.; Jazayeri, S.; Rai, A.; Nikoo, M. Efficacy of Polyunsaturated
Fatty Acids (PUFA) in the Treatment of Attention Deficit Hyperactivity Disorder. J. Atten. Disord. 2017, 21,
78–85. [CrossRef] [PubMed]
89. Barragán, E.; Breuer, D.; Döpfner, M. Efficacy and Safety of Omega-3/6 Fatty Acids, Methylphenidate, and a
Combined Treatment in Children With ADHD. J. Atten. Disord. 2017, 21, 433–441. [CrossRef] [PubMed]
90. Hariri, M.; Djazayery, A.; Djalali, M.; Saedisomeolia, A.; Rahimi, A.; Abdolahian, E. Effect of n-3
supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with
attention-deficit-hyperactivity disorder. Malays. J. Nutr. 2012, 18, 329–335. [PubMed]
91. Matsudaira, T.; Gow, R.V.; Kelly, J.; Murphy, C.; Potts, L.; Sumich, A.; Ghebremeskel, K.; Crawford, M.;
Taylor, E. Biochemical and Psychological Effects of Omega-3/6 Supplements in Male Adolescents with
Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Clinical Trial. J. Child Adolesc.
Psychopharmacol. 2015, 25, 775–782. [CrossRef] [PubMed]
92. Stevens, L.; Zhang, W.; Peck, L.; Kuczek, T.; Grevstad, N.; Mahon, A.; Zentall, S.S.; Eugene Arnold, L.;
Burgess, J.R. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors.
Lipids 2003, 38, 1007–1021. [CrossRef] [PubMed]
93. Sinn, N.; Bryan, J. Effect of Supplementation with Polyunsaturated Fatty Acids and Micronutrients on
Learning and Behavior Problems Associated with Child ADHD. J. Dev. Behav. Pediatr. 2007, 28, 82–91.
[CrossRef] [PubMed]
94. Sinn, N.; Bryan, J.; Wilson, C. Cognitive effects of polyunsaturated fatty acids in children with attention deficit
hyperactivity disorder symptoms: A randomised controlled trial. Prostaglandins Leukot. Essent. Fat. Acids
2008, 78, 311–326. [CrossRef] [PubMed]
95. Dubnov-Raz, G.; Khoury, Z.; Wright, I.; Raz, R.; Berger, I. The effect of α-linolenic acid supplementation on
ADHD symptoms in children: A randomized controlled double-blind study. Front. Hum. Neurosci. 2014,
8, 780. [CrossRef] [PubMed]
96. Raz, R.; Carasso, R.L.; Yehuda, S. The influence of short-chain essential fatty acids on children with
attention-deficit/hyperactivity disorder: A double-blind placebo-controlled study. J. Child Adolesc.
Psychopharmacol. 2009, 19, 167–177. [CrossRef] [PubMed]
97. Dashti, N.; Hekmat, H.; Soltani, H.R.; Rahimdel, A.; Javaherchian, M. Comparison of therapeutic effects of
omega-3 and methylphenidate (ritalin(®)) in treating children with attention deficit hyperactivity disorder.
Iran. J. Psychiatry Behav. Sci. 2014, 8, 7–11. [PubMed]
98. Perera, H.; Jeewandara, K.C.; Seneviratne, S.; Guruge, C. Combined ω3 and ω6 Supplementation in
Children With Attention-Deficit Hyperactivity Disorder (ADHD) Refractory to Methylphenidate Treatment.
J. Child Neurol. 2012, 27, 747–753. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2608 25 of 25
99. Voigt, R.G.; Llorente, A.M.; Jensen, C.L.; Fraley, J.; Berretta, M.; Heird, W. A randomized,
double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with
attention-deficit/hyperactivity disorder. J. Pediatr. 2001, 139, 189–196. [CrossRef] [PubMed]
100. Campoy, C.; Escolano-Margarit, M.V.; Anjos, T.; Szajewska, H.; Uauy, R. Omega 3 fatty acids on child growth,
visual acuity and neurodevelopment. Br. J. Nutr. 2012, 107, S85–S106. [CrossRef] [PubMed]
101. Innis, S.M. Fatty acids and early human development. Early Hum. Dev. 2007, 83, 761–766. [CrossRef]
[PubMed]
102. Agostoni, C.; Mazzocchi, A.; Leone, L.; Ciappolino, V.; Delvecchio, G.; Altamura, C.; Brambilla, P.
The first model of keeping energy balance and optimal psycho affective development: Breastfed infants.
J. Affect. Disord. 2017, 224, 10–15. [CrossRef] [PubMed]
103. Clandinin, M.T.; Chappell, J.E.; Leong, S.; Heim, T.; Swyer, P.; Chance, G. Extrauterine fatty acid accretion in
infant brain: Implications for fatty acid requirements. Early Hum. Dev. 1980, 4, 131–138. [CrossRef]
104. Martinez, M. Tissue levels of polyunsaturated fatty acids during early human development. J. Pediatr. 1992,
120, S129–S138. [CrossRef]
105. Innis, S.M. Omega-3 Fatty acids and neural development to 2 years of age: Do we know enough for dietary
recommendations? J. Pediatr. Gastroenterol. Nutr. 2009, 48 (Suppl. S1), S16–S24. [CrossRef] [PubMed]
106. Williams, C.; Birch, E.E.; Emmett, P.M.; Northstone, K. Stereoacuity at age 3.5 y in children born full-term
is associated with prenatal and postnatal dietary factors: A report from a population-based cohort study.
Am. J. Clin. Nutr. 2001, 73, 316–322. [PubMed]
107. Bloch, M.H. Qawasmi A Omega-3 fatty acid supplementation for the treatment of children with
attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J. Am. Acad.
Child Adolesc. Psychiatry 2011, 50, 991–1000. [CrossRef] [PubMed]
108. Sonuga-Barke, E.J.S.; Brandeis, D.; Cortese, S.; Daley, D.; Ferrin, M.; Holtmann, M.; Stevenson, J.;
Danckaerts, M.; van der Oord, S. Nonpharmacological Interventions for ADHD: Systematic Review and
Meta-Analyses of Randomized Controlled Trials of Dietary and Psychological Treatments. Am. J. Psychiatry
2013, 170, 275–289. [CrossRef] [PubMed]
109. Puri, B.K.; Martins, J.G. Which polyunsaturated fatty acids are active in children with attention-deficit
hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of
randomized controlled trials. Prostaglandins Leukot. Essent. Fat. Acids 2014, 90, 179–189. [CrossRef] [PubMed]
110. Richardson, A.J.; Montgomery, P. The Oxford-Durham study: A randomized, controlled trial of dietary
supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005, 115,
1360–1366. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
